CureVac says COVID vaccine produced immune response in early-stage trial Business, R&D, Therapeutics Germany’s CureVac AG said on Friday its second-generation COVID-19 vaccine produced virus-neutralizing antibodies against the BA.1 subvariant of Omicron, based on preliminary data from an early-stage trial. Read more January 6, 2023/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2022/07/CureVac-Reuters-2022.webp 548 800 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2023-01-06 08:53:302023-01-06 09:52:10CureVac says COVID vaccine produced immune response in early-stage trial
